PubMed

Practical aspects of treatment with drotrecogin alfa (activated).

Camporota L, Wyncoll D.

Crit Care. 2007;11 Suppl 5:S7. Review.PMID: 18269694 [PubMed - indexed for MEDLINE]Related articlesFree article

[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain]

Sacristán JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P.

Gac Sanit. 2004 Jan-Feb;18(1):50-7. Spanish. PMID: 14980173 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.

Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D.

J Crit Care. 2003 Dec;18(4):217-27. Erratum in: J Crit Care. 2004 Mar;19(1):66. PMID: 14691895 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):1-11.PMID: 12544986 [PubMed - indexed for MEDLINE]Related articles

An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW.

Pharmacoeconomics. 2003;21(18):1331-40.PMID: 14750900 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Frampton JE, Foster RH.

Pharmacoeconomics. 2004;22(7):445-76. Review.PMID: 15137883 [PubMed - indexed for MEDLINE]Related articles

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

McCoy C.

Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.PMID: 15500421 [PubMed - indexed for MEDLINE]Related articles

Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.

Durthaler JM, Ernst FR.

Am J Health Syst Pharm. 2006 Aug 1;63(15):1453-60. No abstract available. PMID: 16849712 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.

Ridley S, Lwin A, Wyncoll D, Lippett S, Watson D, Gunning K, Higgins D.

Eur J Anaesthesiol. 2008 Mar;25(3):211-6. Epub 2007 Nov 22.PMID: 18031590 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.

Riou França L, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B.

Int J Technol Assess Health Care. 2006 Winter;22(1):101-8.PMID: 16673686 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):7-9.PMID: 17323514 [PubMed - indexed for MEDLINE]Related articles

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.PMID: 12720562 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.

Davies A, Ridley S, Hutton J, Chinn C, Barber B, Angus DC.

Anaesthesia. 2005 Feb;60(2):155-62.PMID: 15644013 [PubMed - indexed for MEDLINE]Related articles

Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand.

Finfer S, Felton T, Blundell A, Lipman J; ANZICS Clinical Trials Group Sepsis Investigators.

Anaesth Intensive Care. 2006 Apr;34(2):184-90.PMID: 16617638 [PubMed - indexed for MEDLINE]Related articles

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

Chest. 2004 Jun;125(6):2206-16.PMID: 15189943 [PubMed - indexed for MEDLINE]Related articlesFree article

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.PMID: 17973539 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) for severe sepsis.

[No authors listed]

Drug Ther Bull. 2006 Jan;44(1):5-8. Review.PMID: 16425899 [PubMed - indexed for MEDLINE]Related articles

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group.

Intensive Care Med. 2003 Jun;29(6):894-903. Epub 2003 Apr 24.PMID: 12712239 [PubMed - indexed for MEDLINE]Related articles

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. Review.PMID: 18269692 [PubMed - indexed for MEDLINE]Related articlesFree article

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.

Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes J.

Crit Care Med. 2005 Oct;33(10):2266-77.PMID: 16215381 [PubMed - indexed for MEDLINE]Related articles